https://doi.org/10.4081/hmr.v1i9.323

Clinical trials with angiogenesis inhibitors

Vol. 1 No. 9: 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005
Published: June 3, 2009
Abstract Views: 170
PDF: 172
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

G Giaccone
support@pagepress.org
H van Cruijsen
Angiogenesis is essential for tumor growth and metastasis formation. Many agents have been developed to inhibit this process. Two major anti-angiogenic strategies have been so far mostly developed: the vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab and several tyrosine kinase inhibitors (TKI) to VEGF receptors. Bevacizumab is the first specific anti-angiogenic agent registered. This registration was based on the results of the phase III trial which compared first-line chemotherapy plus bevacizumab to chemotherapy alone in patients with metastatic colorectal cancer. Treatment with chemotherapy plus bevacizumab resulted in higher response rates (chemotherapy, 35%, chemotherapy plus bevacizumab, 45%) and longer median survival (chemotherapy, 15.6 months, chemotherapy plus bevacizumab, 20.3 months).1

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Giaccone, G., & van Cruijsen, H. (2009). Clinical trials with angiogenesis inhibitors. Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.323
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).